Jamieson is delighted to announce that it has advised the management team of Affidea on the sale of the business from B-FLEXION to Groupe Bruxelles Lambert. Jamiesons role was to advise the Company on the securing of retention arrangements going into the sale along with the terms of the go forward equity management arrangements with the new owner.
Affidea is the leading provider of healthcare diagnostic services in Europe, and GBL will invest up to EUR 1.0 billion of equity for the transaction. Affidea’s majority shareholder B-FLEXION will fully exit its stake, and management will re-invest alongside GBL. This investment in a defensive sector provides both resilience and portfolio diversification.
Founded in 1991, Affidea is the leading European diagnostic imaging player, with more than 300 centers operating across 15 countries. Affidea has expanded its offering across the value chain, providing an integrated pathway in advanced diagnostics, outpatient and cancer care services with an outstanding quality and value of care. Providing accurate diagnostics is paramount for delivering appropriate treatment. GBL will support Affidea in the development of high-quality medical services in the interest all of its stakeholders – patients, doctors and regulators. Together with management, GBL plans to further strengthen Affidea’s leading platform in its core markets as well as accelerate M&A into new, attractive and fragmented European markets.
Stuart Coventry, Stephen Maxwell and Billy Henson advised the management team on the transaction.
